Burning Rock Biotech Limited (BNR) Stock

Burning Rock Biotech Limited, headquartered in Guangzhou, China, specializes in the development and provision of advanced cancer therapy selection tests across the People's Republic of China. Established in 2014, the company operates through three distinct segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. Burning Rock Biotech is renowned for its comprehensive portfolio of next-generation sequencing-based tests, which enable precise therapy selection and prognosis prediction for various cancer types. These tests utilize both tissue and liquid biopsy samples, covering a wide spectrum including lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers.

Among its leading products are OncoCompass IO and OncoScreen IO, tailored for liquid and tissue biopsy samples respectively, providing essential insights into cancer treatment pathways. Additionally, the company offers specialized tests like OncoCompass Target for ctDNA analysis in non-small cell lung cancer (NSCLC), and ColonCore, which assesses microsatellite instability (MSI) and identifies mutations linked to gastrointestinal cancers. Burning Rock Biotech has also established strategic partnerships to enhance its capabilities, including agreements with Myriad Genetics, Inc. for Myriad myChoice tumor testing and Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients in China.

Committed to advancing cancer diagnostics and treatment through innovation, Burning Rock Biotech collaborates extensively on clinical trials and research studies with industry leaders such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA. With a strong focus on research and development, the company continues to expand its footprint in precision medicine, striving to improve patient outcomes and quality of life through cutting-edge diagnostic solutions.